Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC

Share :
Published: 26 Apr 2023
Views: 138
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Dr Luis Paz-Ares speaks to ecancer about the safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab ±  chemotherapy in patients with carcinoembryonic antigen-related cell adhesion molecule 5 -positive nonsquamous non-small cell lung cancer.

He explains the results of the study and found tusamitamab ravtansine combined with standard-of-care showed encouraging anti-tumour activity across all treatment arms with a favourable safety profile, including in the T4 arm. There were no new safety concerns.

Dr Paz-Ares concludes by explaining how the results of this trial could impact the future treatment of NSCLC.